ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Alkermes and Takeda side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AlkermesTakeda
studies on the registry931,754
open to participants now886
phase 3 studies under way644
reach primary completion within a year647
programswith a study of their own in two years225

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAlkermesTakeda
Phase 100%

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
Phase 2

Alkermes: 1 of its 2 programs at phase 2

  1. ALKS 7290phase 2
50%

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%
Phase 3

Alkermes: 1 of its 2 programs at phase 3

  1. alixorextonphase 3
50%

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%
Approved, new studies00%

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Alkermes2 readouts · 0 phase 3

Alkermes, Nov ’26: 1 program whose next study reaches primary completion

  1. alixorextonphase 3 · Nov 0 · NCT06843590
·······

Alkermes, Jul ’27: 1 program whose next study reaches primary completion

  1. ALKS 7290phase 2 · Jul 0 · NCT07755410
···
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Alkermes

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionAlkermesTakeda
Narcolepsyboth · compare here

Alkermes in Narcolepsy: 1 program

  1. alixorextonphase 3

Their studies: Alkermes’ studies of Narcolepsy in search

Takeda in Narcolepsy: 2 programs

  1. TAK-360phase 3
  2. oveporextonphase 3

Their studies: Takeda’s studies of Narcolepsy in search

Attention Deficit Disorder with Hyperactivityboth · compare here

Alkermes in Attention Deficit Disorder with Hyperactivity: 1 program

  1. ALKS 7290phase 2

Their studies: Alkermes’ studies of Attention Deficit Disorder with Hyperactivity in search

Takeda in Attention Deficit Disorder with Hyperactivity: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Attention Deficit Disorder with Hyperactivity in search

Depressive Disorder, Majorboth · compare here

Alkermes in Depressive Disorder, Major: 1 program

  1. ALKS 7290phase 2

Their studies: Alkermes’ studies of Depressive Disorder, Major in search

Takeda in Depressive Disorder, Major: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Depressive Disorder, Major in search

Idiopathic Hypersomniaboth · compare here

Alkermes in Idiopathic Hypersomnia: 1 program

  1. alixorextonphase 3

Their studies: Alkermes’ studies of Idiopathic Hypersomnia in search

Takeda in Idiopathic Hypersomnia: 1 program

  1. TAK-360phase 3

Their studies: Takeda’s studies of Idiopathic Hypersomnia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Alkermes 0 of 2 · Takeda 12 of 25 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.